Stempeutics Research Pvt. Ltd.

Stempeutics – one of India's ten hottest start ups in 2008

Located at Manipal Hospital, Bangalore, Stempeutics leverages the group's healthcare infrastructure. This gives us access to trained physicians and surgeons in developing a delivery mechanism for stem cell therapies.

Keeping in mind the global burden of diseases and disorders, Stempeutics has made a strategic move to operate out of its facilities in Manipal and Malaysia. We plan to set up operations in other locations, across the globe. This will help to enhance the availability of this novel therapeutics and we truly would be "Regenerating Hope".

Our focus is to carry out research in bone marrow derived Mesenchymal stem cells to be used for both autologous and allogenic therapeutic treatment of various degenerative diseases.

Quality Policy
Stempeutics is committed to deliver safe, effective and affordable stem cell therapies in a "Bench to Bedside" approach, by nurturing cutting edge research and clinical applications and by matching customer satisfaction for "Regenerating Hope".

Stempeutics endeavours to maintain scientific and ethical practices through a Quality Management System in accordance with accepted national and international norms.

Stempeutics will accomplish this through dedicated efforts of its team to continually monitor and improve the effectiveness of the Quality Management System to excel and innovate there by reflecting that we are truly "Inspired by Life".

Recognitions
Stempeutics Research Bangalore gets ISO 9001:2000 certification
Stempeutics Research Bangalore has been awarded ISO 9001:2000 certification for "Processing and Development of Stem Cells" by TUV Rheinland in Aug 2008

BioNexus Status
Stempeutics is the first international company in Malaysia to get the BioNexus status by Malaysian Biotechnology Corporation SDN BHD.

Datuk Iskandar Mizal Mahmood, CEO of Malaysian Biotechnology Corporation Sdn Bhd, said he was pleased with the Manipal Group's commitment to develop Malaysia as a stem cell research and therapy hub and stated "This commitment will help to build a strong human resource foundation in Malaysia for all the stem cell industry and research institutes."  

ICMR
Stempeutics stem cell research centre at Bangalore has been approved by Indian Council of Medical Research for Stem Cell Research activities.

Bio Malaysia
At the Bio Malaysia, Stempeutics' innovations were shortlisted for the "achievement area" display among the exhibitors.  

Awards & Selections

• Our scientist was awarded the Department of Biotechnology (DBT) - Government of India, Overseas Associate-ship for Niche Areas in Biotechnology.
• Our Scientist was selected for the Indian National Science Academy (INSA) Bilateral Exchange Program with Czech Republic.

Stem Cell Therapies are offered for the following diseases:

• Parkinsons Disease
• Spinal Cord Injury
• Critical Limb Ischemia
• Avascular Necrosis
• Motor Neuron Disease
• End Stage Liver Disease
• Psoriasis
• Vitiligo
• Myocardial Infarction

Please Click Here to request more information from Stempeutics Research Pvt. Ltd.

Our Mission
Our mission is to ethically and scientifically explore the full potential of stem cells to transform medicine and offer new hope to millions of people.

Please Click Here to request more information from Stempeutics Research Pvt. Ltd.

Stempeutics is collaborating with few hospitals in conducting experimental stem cell therapies as a proof of concept using bone marrow derived Mesenchymal stem cells in patients suffering from various diseases which as of now are difficult to cure or have no cure.

At regular intervals, these patients will undergo followed-up to assess the effect of the stem cells. These experimental therapies are for the following diseases:

Parkinsons Disease
Parkinsons disease is a neurodegenerative disorder, symptomatized by tremors, rigidity, bradykinesia etc. There is selective degeneration of the dopaminergic neurons in the midbrain region of the brain. Our hypothesis is that the transplanted stem cells will home to the above said region based on the internal mileu and differentiate into dopaminergic neurons, thus alleviating the symptoms.

Spinal Cord Injury
Spinal cord injury is one of the major neurological disabilities often encountered in clinical scenario. Unfortunately most traumas to spinal cord are irreversible and cause permanent disability having no option for further recovery. The Spinal cord injury patients will receive adult mesenchymal Stem Cell therapy, along with standard of care and Neuro-rehabilitation. Our hypothesis is that the injected mesenchymal stem cells having neuro regeneration potential migrate to the site of injury and replace the damaged nervous tissue with healthy functional cells, improving neurological function and quality of life.

Critical Limb Ischemia
Critical limb ischemia patients have severe pain in the affected leg at rest, ulcers or gangrene, as a result of atherosclerosis or vasculitis in leg arteries. Prognosis of the diseases is poor especially in patients who are not amenable for revascularization procedures like angioplasty or bypass procedures, have no option other than undergoing Amputation of the affected leg. Transplantation of bone marrow derived stem cells or mesenchymal stem cells having Neoangiogenic and myogenic potential is a possible treatment option for treating CLI.

Avascular Necrosis
Avascular necrosis or osteonecrosis or aseptic (bone) necrosis or ischemic bone necrosis, is a disease resulting from the temporary or permanent loss of the blood supply to the bones. Due to lack of blood supply, the bone tissue dies and causes the bone to collapse. If the process involves the bone near to a joint, it often leads to collapse of the joint surface. A variety of methods are now used to treat Avascular necrosis, the most common being the total hip replacement (THR). However, THRs have a number of downsides including a long recovery time and short life span of the replacements. Hence Adult Mesenchymal Stem cells by its Angiogenic and Osteogenic properties, have a great therapeutic potential in these ailments which are difficult to treat with existing modalities of treatment.

Motor Neuron Disease
Motor Neuron disease is one of the progressive degenerative neurological disorders having no effective treatment. It dramatically reduces the life span and the quality of life of the patient. Hence the ideal curative treatment in these cases would be the replacement of degenerated or lost cells. The transplanted Adult mesenchymal stem cells have the potential to differentiate into functional neural cell types, thereby facilitating a possible cure.

End Stage Liver Disease
The prevalence of end stage liver disease has increased alarmingly over the last few years. It is rapidly fatal and the current treatment involves a complicated process of liver transplantation. The usage of stem cell therapy is successfully being tried all over the world in end stage liver disease. The idea behind the therapy is that the cells would home into the damaged/degenerated liver and stop the disease process. Subsequently we can hope to see the injected cells regenerate / differentiate into new functional liver cells thereby reviving metabolically the most important organ in the body needed for survival.

Psoriasis
Psoriasis is considered an autoimmune disorder in which there is overproduction of skin resulting from an immune dysfunction. Mesenchymal stem cells have been found to have Immunomodulatory and immunosuppressive properties. Administration of mesenchymal stem cells in a patient with psoriasis will correct the aberrant immune system of his/her body and reduce progression of disease. If successful, this can significantly improve the quality of life of a patient with psoriasis.

Vitiligo
The goal of therapy in vitiligo is to regenerate the damaged colour producing cells of the skin (melanocytes) and to correct the aberrant immune system. Normally, in vitiligo, the body's own immune system attacks and damages the colour producing cells of skin, hence it is considered as an autoimmune disease. Mesenchymal stem cells have been found to have Immunomodulatory and immunosuppressive properties. Administration of mesenchymal stem cells in vitiligo will prevent further damage to melanocytes and reduce progression of disease. In unstable vitiligo, if stabilization can be achieved other therapies like surgery can be used for further management.

Myocardial Infarction
Myocardial infarction is the single largest killer world over. One of the Contributing factor is the irreversible loss of the cardiomyocytes after myocardial infarction. This combined with the absence of an adequate endogenous repair mechanism the injured myocardium usually is replaced by a fibrous scar tissue which complicates into progressive heart failure. The standard protocols of care for acute myocardial Infarction can only alleviate the symptoms but do not have the capacity of myocardial regeneration. The mesenchymal stem cells having potential of myocardial regeneration and angiogenesis can replace the damaged myocardium with functional tissue, thereby preventing eventual complication of heart failure in Myocardial infarction.

Hospitals collaborating with Stempeutics takes IC- SCRT and IEC approval before starting the experimental therapies as per ICMR guidelines.

Please Click Here to request more information from Stempeutics Research Pvt. Ltd.

Board of Directors

Dr. Ramdas Pai
Eminent Educationist, Chairman of Board

Dr. Pai conceptualized, articulated and implemented the Global Delivery Model of Education at Manipal. Dr. Pai’s contributions to education have been recognized nationally and internationally. He has been awarded the Ernst & Young 'Entrepreneur of the Year' 2004 in the Services category. He received the Dr. B C Roy National Award from the President of India in 1993 and was named a National Professor by the Indian Medical Association in 1992.

Dr. Ramdas Pai was appointed as Honorary Professor of International Health by the University of Minnesota Medical School in 1999. Dr. Pai has been a member of the Medical Council of India and National Assessment and Accreditation Council (NAAC). He has been nominated by the Union Minister of Human Resource Development to a special six-member committee to advise the Ministry of Higher Education.
     

Dr. Ranjan Pai
CEO, Manipal Education & Medical Group International India Pvt. Ltd.

Dr. Ranjan Pai is the CEO of Manipal Education and Medical Group International India Pvt Ltd. He set up the Manipal Education and Medical Group (MEMG), the corporate entity responsible for the administration of new and existing hospitals and the education institutions of the group. He is responsible for setting up the Melaka Manipal Medical College, Malaysia as an international project and a world-class medical and education center.

Dr. Pai also established Manipal Universal Learning, engaged in Distance Education and professional skills education. He is a graduate of Kasturba Medical College, Manipal and has studied Hospital Administration in the United States. Dr. Ranjan Pai’s focus is on the new initiatives of the group.
     

Dr. H S BallalPro-Chancellor, Manipal University

As Pro-Chancellor of Manipal University, Dr. Ballal is responsible for the challenges of running India’s first private University and maintaining academic standards for both faculty and students. Dr. Ballal has been an active member of Indian Medical Association and was elected President of Indian Medical Association, Dakshin kannada. He has held several positions in Indian Radiology and Imaging Associations and has published several papers in reputed journals.

Known for his dynamism and teamwork, Dr. Ballal recently implemented innovations in patient care and clinical teaching. He directs the activities of the University in academics and regulatory issues for the present and as a foundation for the future.
     

Mr. B N Manohar
President, Stempeutics Research Pvt. Ltd.

Manohar has been associated with the Manipal Group since Jan 2002 and has taken up the role of President at Stempeutics in August 2007. Prior to this Manohar has worked as a Chief Executive, Manipal Universal Learning, handling on Line Assessment business, Engineering Twinning Program, Global Nursing Program, Vocational Education and E-content development. He also had a stint at the Group level (MEMG) as Chief Information Officer and Chief Executive – Strategic Projects.

Prior to Joining Manipal Group, Manohar has had long and successful stints at Wipro GE Medical Systems, Lucas TVS and W.S.Industries. Manohar has a rich domain expertise in strategy planning for various industry segments, Business Development, Process Re-engineering, Business System integration and leveraging IT Technology for service operations. Manohar has done his B.E. from Regional Engineering College, Trichy and M.E. from Guindy Engineering College, Chennai.
     

Dr. Satish Totey Ph.D
Chief Scientific Officer, Stempeutics Research Pvt. Ltd.

Dr. Satish Totey is among a select number of researchers who pioneered the isolation and characterization of pluripotent stem cells from human embryo, which provided an important framework for the development of human embryonic stem cell lines. He also developed technology for up- scaling of mesenchymal stem cells and is currently conducting phase-I clinical trials for myocardial infarction, leg ischemia, spinal cord injury and optic nerve injury. He has 92 research papers and 12 US patents to his credit.

Dr. Satish Totey is a Ph.D from Jawaharlal Nehru University, New Delhi.

Management Team

Mr. B N Manohar
President.

Manohar has been associated with the Manipal Group since Jan 2002 and has taken up the role of President at Stempeutics in August 2007. Prior to this Manohar has worked as a Chief Executive, Manipal Universal Learning, handling on Line Assessment business, Engineering Twinning Program, Global Nursing Program, Vocational Education and E-content development. He also had a stint at the Group level (MEMG) as Chief Information Officer and Chief Executive - Strategic Projects.

Prior to Joining Manipal Group, Manohar has had long and successful stints at Wipro GE Medical Systems, Lucas TVS and W.S.Industries. Manohar has a rich domain expertise in strategy planning for various industry segments, Business Development, Process Re-engineering, Business System integration and leveraging IT Technology for service operations.

Manohar has done his B.E. from Regional Engineering College, Trichy and M.E. from Guindy Engineering College, Chennai.

Dr. Satish Totey, Ph.DChief Scientific Officer.

Dr. Satish Totey is among a select number of researchers who pioneered the isolation and characterization of pluripotent stem cells from human embryo, which provided an important framework for the development of human embryonic stem cell lines. He also developed technology for up- scaling of mesenchymal stem cells and is currently conducting phase-I clinical trials for myocardial infarction, leg ischemia, spinal cord injury and optic nerve injury at Manipal Hospital, Bangalore. He has 89 research papers and 8 US patents to his credit.

Dr. Satish Totey is a Ph.D from Jawaharlal Nehru University, New Delhi.

Dr. Vijay Sharma, Ph.DVice President - Operations, Bangalore.

Dr. Vijay Sharma heads Stempeutics Bangalore Operations. He has been associated with the Manipal Group, since June 2004. Since then, he has been instrumental in developing new molecular based assays. He has been instrumental in devising the nucleic acid testing for blood bags, the first of its kind in the country. He has served as Dean - Manipal Institute of Regenerative Medicine before Dr Pawan.

Dr Vijay is in-charge of Stem Cell Labs, Quality Systems, Experimental Therapies/Clinical Trials and Business Development.

Dr. Vijay is a Ph.D from Bombay University.

Dr (Lt Col) Pawan Kumar Gupta, MD, DNB (Path), PhD (Haemat)Director - Clinical Research

Dr. Gupta has taken up the role of Director - Clinical Research effective Oct 1st 2008. Before joining Stempeutics, he was an Associate Professor, Dept of Pathology, Haematopathology & Transfusion Medicine, Armed Forces Medical College, Pune. Along with this, he was also Officer-in-charge for: Specialized Hematological Laboratory which includes morphological diagnosis and coagulation parameters of the disease, Molecular diagnosis laboratory for different hematological disorders, Stem Cell Laboratory, Blood Bank, Component Laboratory and Infectious disease screening laboratory of the Armed Forces in Pune and Flow Cytometry laboratory (Haematology). He had served the Armed Forces for past 24 years and he has a vast experience in Pathology, Haematopathology, Transfusion Medicine and Stem Cells.
 
Dr Gupta is an MD (Pathalogy) (AFMC, Pune), Diplomate of National Board of Examination (Pathology) and PhD (Haematology- AIIMS). Dr Gupta is also the Dean of Manipal Institute of Regenerative Medicine.

Mr. M K MadhuKumarCountry Manager, Malaysia

Madhu has taken up the role of Country Manager, Malaysia in Jan 2008. He heads the newly formed entity Stempeutics Research Malaysia Sdn Bhd.

Madhu has over 16 years of rich and diverse experience in the Healthcare Industry encompassing Market Research, Product Management, Business Development, Sales Force Management and Public Relations. He had long & successful stints at Johnson & Johnson and IBA Health (India). He has earlier worked for our Group - Manipal Health Systems as GM - Marketing for nearly three years.

Madhu is a science graduate from MG University, Kerala and also completed his Masters in Marketing Management from K.J. Somaiya Institute of Management Studies.

Please Click Here to request more information from Stempeutics Research Pvt. Ltd.

What are Patients Saying...

"It is a big relief to be able to grip things and to pass urine by myself without the need for a catheter. Soon I will be able to walk normally."
Ramesh
Spinal cord injury

"No treatment has been so effective."
Andrew Kisana
Parkinson's disease

"Am thankful to all the doctors and surgeons, as they gave me a new lease of life."
Prabha Ben
Spinal cord injury

Please Click Here to request more information from Stempeutics Research Pvt. Ltd.

Publications

Publications from Embryonic Stem Cell Group:

• Deb KD, Devi Prakash A, Sharma V, Totey S (2007) Embryonic Stem Cells: From Markers to Market. Rejuvenation Research. 10(4) E-published
• Sivasubramaniyan K, Atluri RR, Sarda K, Arvind M, Balaji V, Deb KD. (2008) Endotoxin induced silencing of mesoderm induction and functional differentiation: Role of the DNA-binding cytokine HMGB1 in pluripotency and infection. Regenerative Medicine 3: (1): 23-31.
• Saxena S, Hanwate M, Sharma V, Deb K, Totey S. (2008) Derivation of FGF2 secreting human fibroblast feeder cells from embryoid bodies: A novel culture system for embryonic stem cells. Mol Reprod Dev (In Press)
• Jaiswal YK, Jaiswal MK, Agrawal V, Deb K (2007) Maternal Gram-negative bacterial infection induced apoptosis of the implanting blastocyst. Journal of Turkish-German Gynecology Association. 7 (4)
  Deb KD (2007) Endotoxins Alter the Expression of HMGB1 and the Genes of Mesoderm Lineages in Human Embryoid Bodies. Supplement JTGGA. p 21
• Deb KD, Sarda K (2007) Embryonic Stem Cells: Preclinical perspectives. Journal of Translational Medicine (communicated)
• Sivashubramaniyan K, Balaji V, Arvind M, Bhatt V, Deb KD. (2007) Y-27632 can induce differentiation of cystic embryoid bodies to trophoblast like cells. Differentiation (Communicated)
• Deb KD, Vishnu Balaji, Kavitha S, Nair K, Sharma CP (2007) Derivation of embroid bodies from human embryonic stem cells grown on biomimetic membranes with controlled ligand supplementation. Biomaterials (Communicated)
• Sivashubramaniyan K, Arvind M, Sarda K, Saxena S, Totey S, Bhatt V, Deb KD (2007) Silver nanoparticles prevents differentiation of hESCs by improving IGF2 secretion from niche cells. Nature Materials (Communicated)
• Kavitha Sivasubramaiyan, Arvind M, Shobhit S, Totey S, Sarda K, Deb K (2007) Redefining the niche in human embryonic stem colonies: Role of Rho kinases in improving ESC culture and directing differentiation towards early trophectoderm like niche cells (TNhC) Cell Stem Cells (Communicated)

News

Stempeutics Research
Bangalore has received ISO 9001:2000 certification by TUV Rheinland
World class stem cell lab at Manipal
Stempeutics started world class stem cell lab at Manipal in collaboration with Manipal University for Research & Pilot studies

Stempeutics signed an agreement with Asiri Hospitals Ltd
Stempeutics signed an agreement with Asiri Hospitals Ltd in Colombo for starting Stem Cell therapies in Sri Lanka

Clinical trials started
Stempeutics starts clinical trials for Acute Myocardial Infarction and Critical Limb Ischemia

Business Today
Stempeutics has been selected as one of the ten hottest start ups in 2008 by Business Today

Pilot Studies
Stempeutics starts pilot studies for Vitiligo and End Stage Liver Disease with Manipal Hospital, Bangalore

Please Click Here to request more information from Stempeutics Research Pvt. Ltd.